Skip to NavigationSkip to content

Top Ten most popular articles on this week!

Published on 10/05/19 at 09:26am

This week was a particularly bad one for the NHS after it was revealed thousands of EU nurses were leaving while the number of GPs had gone into decline for the first time in 50 years. Meanwhile our feature looked at the NHS Long Term Plan and asked to what extent mHealth will go towards solving the problems of the overstretched National Health Service.

Meanwhile Eli Lilly showed positive Phase 3 results with its migraine treatment Emgality while GSK and Innoviva's triple asthma therapy Trelegy Ellipta showed equally impressive Phase 3 results. Deals were also a theme of this week after Novartis bought dry eye treatment Xiidra for $5.3 billion while Lundbeck bought neuroscience firm Abide Therapeutics for $400 million. To find out more check out this weeks’ top 10 on!  

10. Common diabetes drugs have been linked to a ‘flesh-eating’ genital infection

Patients taking some newer diabetes medications – SGLT2 inhibitors – have been warned that they may be at risk of developing necrotizing fasciitis infections on their genitals.

9. Number of GPs in decline for first time in 50 years

The number of GPs has been in decline, year on year, since 2014. The decline marks the first sustained fall in the number of NHS GPs for more than 50 years.

8. Thousands of EU nurses and midwives leave NHS because of Brexit

Nearly 5,000 EU nurses and midwives have left the NHS over the past two years.

7. Novartis buys dry eye treatment Xiidra in deal worth $5.3 billion

Japanese multinational Takeda Pharmaceutical has agreed to sell its dry eye drug Xiidra to Swiss firm Novartis in a deal worth as much as $5.3 billion.

6. Pfizer scores conditional European approval in ALK-positive lung cancer with Lorviqua

Pfizer’s Lorviqua (lorlatinib), or Lorbrena as it is known in the US, Canada and Japan, has just been awarded conditional marketing approval from the European Commission for the treatment of anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC), according to the company.

5. US prescription drugs most expensive in world, analysis shows

Brand name prescription drugs cost on average 4.3 times more in the United States than in the UK, according to research from Johns Hopkins Bloomberg School of Public Health.

4. Lundbeck acquire Abide Therapeutics in deal worth $400 million

Danish firm Lundbeck has agreed to acquire San Diego-based biotech Abide Therapeutics as part of a deal worth $400 million.

3. GSK and Innoviva's triple asthma therapy Trelegy Ellipta impresses at Phase 3

GSK and partner Innoviva have lifted the curtain on new Phase 3 data for their single inhaler triple therapy Trelegy Ellipta in the treatment of uncontrolled asthma, showing that it met its primary endpoint.

2. Feature: Will mobile phones save the NHS?

The NHS is sick. According to politicians and NHS chiefs, the cure involves a strong dose of mHealth. Louis Goss asks to what extent mobile health apps can solve the problems of the increasingly strained health service.

1. Eli Lilly's Emgality shows positive Phase 3 results in treatment of migraine

Eli Lilly has announced positive results from the Phase 3 EVOLVE-1 and EVOLVE-2 trials looking into Emgality (galcanezumab-gnlm) for the treatment of episodic migraine.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches